GHENT, Belgium, 25 October 2017 (1 pm CEST) - Trading in the shares of Ablynx NV [Euronext Brussels: ABLX; OTC: ABYLY] was suspended at the request of the Company on 25 October 2017 as from 1 pm CEST.
This suspension occurs in connection with the initial U.S. public offering which priced yesterday, 24 October 2017, and is comprised of a public offering of ordinary shares in the form of American Depositary Shares. The trading halt on Euronext Brussels is performed as a precautionary measure to allow the underwriters in the offering to communicate allocations to investors and to facilitate a debut open of the American Depositary Shares on the NASDAQ Global Select Market.
Trading on the regulated market of Euronext Brussels will resume tomorrow 26 October 2017 at the opening of the stock exchange. The American Depository Shares are expected to begin trading on the NASDAQ Global Select Market later today 25 October 2017 under the symbol "ABLX".
BofA Merrill Lynch, J.P. Morgan and Jefferies are acting as joint book-running managers for the offering. Baird, Bryan, Garnier & Co. and Ladenburg Thalmann are acting as co-managers for the offering.
A registration statement relating to and describing the terms of the offering was declared effective by the U.S. Securities and Exchange Commission on 24 October 2017.
The securities to be issued in the offering are being offered only by means of a prospectus. When available, copies of the final prospectus can be obtained from BofA Merrill Lynch at NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte North Carolina 28255-0001, Attn: Prospectus Department, or by email at firstname.lastname@example.org; from J.P. Morgan at Attn: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (866) 803-9204; or from Jefferies at 520 Madison Avenue, 2nd Floor, New York, New York 10022, Attn: Equity Syndicate Prospectus Department, or by email at Prospectus_Department@Jefferies.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals.
Voor bijkomende informatie, gelieve contact op te nemen met
Dr Edwin Moses
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
Ablynx's media relaties:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
No public offering has been nor will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States and Canada, where any such action is required, including in the European Economic Area. In the European Economic Area, with respect to any Member State that has implemented Directive 2003/71/EC, as amended (together with any applicable implementing measures in any Member State, the "Prospectus Directive"), the transaction to which this press release relates has only been made available to, and has been engaged in only with, qualified investors in that Member State within the meaning of the Prospectus Directive.
In addition, in the United Kingdom, the transaction to which this press release relates has only been made available to, and has been engaged in only with, investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), qualified investors falling within Article 49(2)(a) to (d) of the Order, and other persons to whom this announcement may lawfully be communicated (all such persons together being referred to as "relevant persons"). The securities referred to herein has only been made available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities has been engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.